BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 19458024)

  • 1. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.
    Ahmed A; Turner G; King B; Jones L; Culliford D; McCance D; Ardill J; Johnston BT; Poston G; Rees M; Buxton-Thomas M; Caplin M; Ramage JK
    Endocr Relat Cancer; 2009 Sep; 16(3):885-94. PubMed ID: 19458024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver.
    Citterio D; Pusceddu S; Facciorusso A; Coppa J; Milione M; Buzzoni R; Bongini M; deBraud F; Mazzaferro V
    Eur J Surg Oncol; 2017 Feb; 43(2):380-387. PubMed ID: 27956320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenteric Tumor Deposits in Midgut Small Intestinal Neuroendocrine Tumors Are a Stronger Indicator Than Lymph Node Metastasis for Liver Metastasis and Poor Prognosis.
    Fata CR; Gonzalez RS; Liu E; Cates JM; Shi C
    Am J Surg Pathol; 2017 Jan; 41(1):128-133. PubMed ID: 27684993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
    Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
    BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center.
    Norlén O; Stålberg P; Öberg K; Eriksson J; Hedberg J; Hessman O; Janson ET; Hellman P; Åkerström G
    World J Surg; 2012 Jun; 36(6):1419-31. PubMed ID: 21984144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.
    Mandair D; Khan MS; Lopes A; Furtado O'Mahony L; Ensell L; Lowe H; Hartley JA; Toumpanakis C; Caplin M; Meyer T
    J Clin Endocrinol Metab; 2021 Mar; 106(3):872-882. PubMed ID: 33180939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors influencing survival in small bowel neuroendocrine tumor with liver metastases.
    Manguso N; Nissen N; Hendifar A; Harit A; Mirocha J; Friedman M; Lipshutz HG; Amersi F
    J Surg Oncol; 2019 Nov; 120(6):926-931. PubMed ID: 31396982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making.
    Bertani E; Falconi M; Grana C; Botteri E; Chiappa A; Misitano P; Spada F; Ravizza D; Bazolli B; Fazio N
    Int J Surg; 2015 Aug; 20():58-64. PubMed ID: 26074290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms.
    Maurer E; Heinzel-Gutenbrunner M; Rinke A; Rütz J; Holzer K; Figiel J; Luster M; Bartsch DK
    J Neuroendocrinol; 2022 Jan; 34(1):e13076. PubMed ID: 34964186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastases.
    Guo J; Zhang Q; Bi X; Zhou J; Li Z; Huang Z; Zhang Y; Li M; Chen X; Hu X; Yihebali C; Liang J; Liu J; Zhao J; Cai J; Zhao H
    Oncotarget; 2017 Mar; 8(10):17396-17405. PubMed ID: 28030811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties.
    Kankava K; Maisonneuve P; Mangogna A; Centonze G; Cattaneo L; Prinzi N; Pusceddu S; Fazio N; Pisa E; Di Domenico S; Bertani E; Mazzaferro V; Albertelli M; Grillo F; Milione M
    J Neuroendocrinol; 2021 Aug; 33(8):e13000. PubMed ID: 34268808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study.
    Le Treut YP; Grégoire E; Klempnauer J; Belghiti J; Jouve E; Lerut J; Castaing D; Soubrane O; Boillot O; Mantion G; Homayounfar K; Bustamante M; Azoulay D; Wolf P; Krawczyk M; Pascher A; Suc B; Chiche L; de Urbina JO; Mejzlik V; Pascual M; Lodge JP; Gruttadauria S; Paye F; Pruvot FR; Thorban S; Foss A; Adam R;
    Ann Surg; 2013 May; 257(5):807-15. PubMed ID: 23532105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.
    Pavel M; Baudin E; Couvelard A; Krenning E; Öberg K; Steinmüller T; Anlauf M; Wiedenmann B; Salazar R;
    Neuroendocrinology; 2012; 95(2):157-76. PubMed ID: 22262022
    [No Abstract]   [Full Text] [Related]  

  • 14. Classification of low-grade neuroendocrine tumors of midgut and unknown origin.
    Van Eeden S; Quaedvlieg PF; Taal BG; Offerhaus GJ; Lamers CB; Van Velthuysen ML
    Hum Pathol; 2002 Nov; 33(11):1126-32. PubMed ID: 12454818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subgroup analysis of patients with G2 gastroenteropancreatic neuroendocrine tumors.
    Hauck L; Bitzer M; Malek N; Plentz RR
    Scand J Gastroenterol; 2016 Jan; 51(1):55-9. PubMed ID: 26137871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Factors for Survival among Patients with Small Bowel Neuroendocrine Tumours Associated with Mesenteric Desmoplasia.
    Laskaratos FM; Diamantopoulos L; Walker M; Walton H; Khalifa M; El-Khouly F; Koffas A; Demetriou G; Caplin M; Toumpanakis C; Mandair D
    Neuroendocrinology; 2018; 106(4):366-380. PubMed ID: 29320779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Factors and Survival Time in Patients with Small Bowel Tumors: A Retrospective Observational Study.
    Taghipour Zahir S; Heidarymeybodi Z; AleSaeidi S
    Int J Surg Oncol; 2019; 2019():2912361. PubMed ID: 31186956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
    Mosquera C; Koutlas NJ; Fitzgerald TL
    Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Liver resection for non-colorectal, non-neuroendocrine liver metastases--is hepatic resection justified as part of the oncosurgical treatment?].
    Lehner F; Ramackers W; Bektas H; Becker T; Klempnauer J
    Zentralbl Chir; 2009 Sep; 134(5):430-6. PubMed ID: 19757343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Factors Associated With Progression for Advanced-Stage/G1 and G2 Small-Bowel Neuroendocrine Tumors After Multimodal Therapy: Experience From a Tertiary Referral Center.
    Khetan P; Oyewole F; Wolin E; Kim MK; Divino CM
    Pancreas; 2020 Apr; 49(4):509-513. PubMed ID: 32224719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.